#Epitranscriptomic
[The epitranscriptomic, a new perspective on muscle biology and therapeutic opportunities]

Medecine sciences : M/S · Klein et al.
doi.org/10.1051/medsci/2026175
#RNAsky #RNAmods
[The epitranscriptomic, a new perspective on muscle biology and therapeutic opportunities]
Medecine sciences : M/S · Klein P.
doi.org
November 19, 2026 at 2:10 AM
Long Non-Coding RNAs in Cancer Epigenetic and Epitranscriptomic Modulation: Mechanisms and Clinical Applications as Potential Biomarkers

Critical reviews in oncology/hematology · Samad et al.
doi.org/10.1016/j.critrevonc.2026.105707
#RNAsky #RNAmods
Long Non-Coding RNAs in Cancer Epigenetic and Epitranscriptomic Modulation: Mechanisms and Clinical Applications as Potential Biomarkers
Critical reviews in oncology/hematology · Samad MA, Zaidi SK, Zughaibi TA, Alhashmi MH, Al-Abbasi F, Tabrez S.
doi.org
November 17, 2026 at 9:39 PM
How microbes reprogram immunity through epigenetic and epitranscriptomic regulation

The EMBO journal · Si et al.
doi.org/10.1038/s44318-026-00962-2
#RNAsky #RNAmods
How microbes reprogram immunity through epigenetic and epitranscriptomic regulation
The EMBO journal · Si W, Ding X, Wang L.
doi.org
November 13, 2026 at 1:36 AM
How microbes reprogram immunity through epigenetic and epitranscriptomic regulation
New review article by Wei Si, Xingchen Ding and Liangliang Wang
link.springer.com/article/10.1...
November 10, 2026 at 2:49 PM
Epitranscriptomic regulation contributes to multiple myeloma biology and offers potential therapeutic targets

Neoplasia (New York, N.Y.) · El-Sehrawy et al.
doi.org/10.1016/j.neo.2026.101396
#RNAsky #RNAmods
Epitranscriptomic regulation contributes to multiple myeloma biology and offers potential therapeutic targets
Neoplasia (New York, N.Y.) · El-Sehrawy AAMA, Ibrahim SK, Abdullah SS, Hjazi A, Nayak PP, Tailor NK, Smerat A, Abd SM, Basunduwah TS, Hsu CY.
doi.org
November 12, 2026 at 8:45 PM
📢 The BMCS Hot Topics on Epigenetic and Epitranscriptomic modulation is now open for registration! 📢

✨ This meeting is running in collaboration with our latest collection on ‘Epigenetics and epitranscriptomics’ which is open for submissions!
🔗 blogs.rsc.org/cb/202...

www.rscbmcs.org/even...
November 11, 2026 at 5:42 PM
Paternal zearalenone exposure impairs transgenerational male spermatogenesis via the METTL14-m6A-Thap1-glutathione axis

Environmental research · Chen et al.
doi.org/10.1016/j.envres.2026.126119
#RNAsky #RNAmods
Paternal zearalenone exposure impairs transgenerational male spermatogenesis via the METTL14-m6A-Thap1-glutathione axis
Here, we investigated whether paternal ZEA exposure causes transgenerational male reproductive toxicity and elucidated the associated epitranscriptomic mechanism.
doi.org
November 10, 2026 at 3:06 AM
RNA 5-Methylcytosine (m5C) in Cancer: An Emerging Epitranscriptomic Hub for Therapy Resistance and Clinical Translation https://pubmed.ncbi.nlm.nih.gov/43000109/
November 9, 2026 at 10:13 AM
“A 5′ tRNA-derived fragment tDR-Glu-TTC exacerbates intestinal ischemia/reperfusion injury via ADAR1/autophagy/ROS/necroptosis signaling axis”

tDR-Glu-TTC regulates #Necroptosis via epitranscriptomic editing in intestinal I/R injury ⤵️
www.nature.com/articles/s41...
A 5′ tRNA-derived fragment tDR-Glu-TTC exacerbates intestinal ischemia/reperfusion injury via ADAR1/autophagy/ROS/necroptosis signaling axis - Cell Death & Differentiation
Cell Death & Differentiation - A 5′ tRNA-derived fragment tDR-Glu-TTC exacerbates intestinal ischemia/reperfusion injury via ADAR1/autophagy/ROS/necroptosis signaling axis
www.nature.com
November 3, 2026 at 11:55 AM
Epitranscriptomic regulation of liver regeneration during aging: Editorial on "NAT10 deficiency in aging drives impaired liver regeneration by disrupting PARP10 in an ac4C-dependent manner"

Clinical and molecular hepatology · Jeong et al.
doi.org/10.3350/cmh.2026.0941
#RNAsky #RNAmods
Epitranscriptomic regulation of liver regeneration during aging: Editorial on "NAT10 deficiency in aging drives impaired liver regeneration by disrupting PARP10 in an ac4C-dependent manner"
Clinical and molecular hepatology · Jeong H, Yang YM.
doi.org
October 30, 2026 at 6:31 PM
Calibrated analysis framework for nanopore direct RNA sequencing uncovers cell-specific m6A proportions at conserved sites

bioRxiv · Ohnezeit et al.
doi.org/10.1101/2025.11.02.686099
#RNAsky #RNAmods
Calibrated analysis framework for nanopore direct RNA sequencing uncovers cell-specific m6A proportions at conserved sites
Here, we aimed to establish a best-practice workflow for DRS-based epitranscriptomic analyses.
doi.org
October 24, 2026 at 4:31 PM
💊 Session 2 begins at #NordicCompBio!
🎤 Antonio Federico presents EpiTheraRx, exploring how epitranscriptomic regulation of alternative splicing could open new opportunities for RNA therapeutics.
#RNAtherapeutics #Bioinformatics
October 23, 2026 at 9:41 AM
Integrative m6A epitranscriptomic and transcriptomic analysis in livers of patients with type 2 diabetes mellitus

Genomics · Chen et al.
doi.org/10.1016/j.ygeno.2026.111327
#RNAsky #RNAmods
Integrative m6A epitranscriptomic and transcriptomic analysis in livers of patients with type 2 diabetes mellitus
Here, we integrated mRNA expression profiles extracted from Arraystar Human LncRNA Microarray V5.
doi.org
October 21, 2026 at 11:51 PM
"Beyond the Genetic Blueprint: Disrupting the Epitranscriptomic Code in Myeloproliferative Neoplasms"

Experimental hematology · Soleymani et al.
doi.org/10.1016/j.exphem.2026.105942
#RNAsky #RNAmods
"Beyond the Genetic Blueprint: Disrupting the Epitranscriptomic Code in Myeloproliferative Neoplasms"
Experimental hematology · Soleymani H, Khoshnevisan S, Gholamian S, Sheybani P.
doi.org
October 21, 2026 at 5:58 PM
Multi-omics integration reveals m6A epitranscriptomic regulators as central drivers of a prognostic immune-metabolic axis in glioblastoma

Biochimica et biophysica acta. Proteins and proteomics · Rana et al.
doi.org/10.1016/j.bbapap.2026.141189
#RNAsky #RNAmods
Multi-omics integration reveals m6A epitranscriptomic regulators as central drivers of a prognostic immune-metabolic axis in glioblastoma
Biochimica et biophysica acta. Proteins and proteomics · Rana MS, Parvin MM, Sarker MA, Islam MT, Rahman MM, Wahid A.
doi.org
October 16, 2026 at 11:11 PM
Epigenetic and Epitranscriptomic Regulation of Immune Checkpoint Response in Hepatocellular Carcinoma: Mechanisms, Therapeutic Targeting, and Translational Challenges

Clinical and molecular hepatology · Zhi et al.
doi.org/10.3350/cmh.2026.0745
#RNAsky #RNAmods
Epigenetic and Epitranscriptomic Regulation of Immune Checkpoint Response in Hepatocellular Carcinoma: Mechanisms, Therapeutic Targeting, and Translational Challenges
Clinical and molecular hepatology · Zhi Y, Guo Y, Wei H, Gantier MP, Ma X, Dong Z, Liu K.
doi.org
October 16, 2026 at 11:12 PM
SPEAR: Spatial Epitranscriptomic Analysis by Mass Spectrometry Reveals Localized RNA Modification Remodeling During Glioma Progression #NeuroDegeneration 🧪🧠
https://www.biorxiv.org/content/10.64898/2026.10.13.758238v1
October 16, 2026 at 7:01 PM
SPEAR: Spatial Epitranscriptomic Analysis by Mass Spectrometry Reveals Localized RNA Modification Remodeling During Glioma Progression https://www.biorxiv.org/content/10.64898/2026.10.13.758238v1
October 16, 2026 at 4:48 PM
SPEAR: Spatial Epitranscriptomic Analysis by Mass Spectrometry Reveals Localized RNA Modification Remodeling During Glioma Progression https://www.biorxiv.org/content/10.64898/2026.10.13.758238v1
October 16, 2026 at 4:48 PM
Large-Scale Chemical Space Exploration Identifies DE19725241 as a Candidate Fat Mass and Obesity-Associated Protein-Targeting Compound with Selective Activity in Pancreatic Cancer Cells. Click the link below to read this #open_access article. www.scienceopen.com/hosted-docum...
Large-Scale Chemical Space Exploration Identifies DE19725241 as a Candidate Fat Mass and Obesity-Associated Protein-Targeting Compound with Selective Activity in Pancreatic Cancer Cells
<div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section"><a class="named-anchor" id="d18403095e182"><!-- named anchor --></a><h5 class="section-title" id="d18403095e183">Background:</h5><p dir="auto" id="d18403095e185">Fat mass and obesity-associated protein (FTO), an epitranscriptomic regulator, has been implicated in cancer progression and immune regulation but the therapeutic relevance in pancreatic cancer is unclear.</p></div><div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section"><a class="named-anchor" id="d18403095e187"><!-- named anchor --></a><h5 class="section-title" id="d18403095e188">Methods:</h5><p dir="auto" id="d18403095e190">TCGA and GTEx transcriptomic datasets were analyzed to evaluate FTO expression and prognostic associations in pancreatic cancer. Candidate FTO-targeting compounds were identified by active learning-assisted virtual screening of > 22 million compounds. The lead candidate, DE19725241, was further assessed by binding pose metadynamics, molecular dynamics simulations in multiple environments, MM/GBSA calculations, and <i>in vitro</i> testing in three pancreatic cancer cell lines and one normal pancreatic epithelial cell line.</p></div><div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section"><a class="named-anchor" id="d18403095e195"><!-- named anchor --></a><h5 class="section-title" id="d18403095e196">Results:</h5><p dir="auto" id="d18403095e198">FTO was overexpressed in pancreatic tumors and associated with poorer overall survival. DE19725241 showed favorable predicted interactions with FTO, particularly with ARG-96, TYR-108, and GLU-234, and exhibited moderate but selective antiproliferative activity in pancreatic cancer cells.</p></div><div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section"><a class="named-anchor" id="d18403095e200"><!-- named anchor --></a><h5 class="section-title" id="d18403095e201">Conclusions:</h5><p dir="auto" id="d18403095e203">DE19725241 represents a potential early-stage scaffold for developing FTO-targeted strategies in pancreatic cancer.</p></div>
www.scienceopen.com
October 17, 2026 at 7:53 AM
(BioRxiv All) SPEAR: Spatial Epitranscriptomic Analysis by Mass Spectrometry Reveals Localized RNA Modification Remodeling During Glioma Progression: RNA modifications shape cell identity and disease, yet their spatial organization within tissues has remained largely… #BioRxiv #MassSpecRSS
SPEAR: Spatial Epitranscriptomic Analysis by Mass Spectrometry Reveals Localized RNA Modification Remodeling During Glioma Progression
RNA modifications shape cell identity and disease, yet their spatial organization within tissues has remained largely inaccessible to existing technologies. NGS-based methods can map a limited number of individual modifications with spatial resolution, while liquid chromatography-tandem mass spectrometry (LC-MS/MS) provides comprehensive and quantitative coverage of the epitranscriptome from bulk, homogenized tissue. No current approach combines histological resolution, broad modification coverage, quantitative accuracy, and the sensitivity required for microscale clinical specimens. We present SPEAR (SPatial Epitranscriptomic Analysis by mass spectrometRy), a workflow coupling laser microdissection with a redesigned LC-MS/MS pipeline to enable quantitative epitranscriptomic profiling directly from formalin-fixed, paraffin-embedded (FFPE) tissue. This combination enables reproducible detection of dozens of RNA modifications from regions as small as 0.1 mm2, establishing a spatial scale previously inaccessible to mass spectrometry-based approaches. Applied to serial mouse brain sections, SPEAR resolved anatomically defined epitranscriptomic signatures across white and gray matter, establishing its spatial resolution and reproducibility in a controlled system. We then applied SPEAR to human diffuse gliomas containing, within individual specimens, both primary low-grade tumor regions and discrete foci undergoing transformation toward higher-grade malignancy. SPEAR resolved this transition directly, revealing a coordinated decrease in multiple methylated RNA modifications specifically within higher-grade regions, a spatially restricted signal that was masked by bulk analysis and reproducibly observed across patients despite underlying genetic heterogeneity. SPEAR establishes spatial epitranscriptomics as a tractable approach for molecular profiling of clinical tissue, providing a platform for biomarker discovery and molecular stratification based on the spatial organization of RNA modifications.
dlvr.it
October 16, 2026 at 7:04 PM
Myeloid reprogramming generates myeloid-derived activating cells to potentiate radiotherapy and suppress metastasis
Myeloid reprogramming generates myeloid-derived activating cells to potentiate radiotherapy and suppress metastasis
Ji et al. show that radiotherapy induces a TET2-dependent epitranscriptomic program in myeloid cells that promotes immunosuppressive M-MDSC differentiation. TET2 loss preserves caRNA m5C-MBD6 signaling, restores IRF3-IFN-I activation, generates myeloid-derived activating cells, and enhances radiotherapy-induced antitumor immunity.
dlvr.it
October 15, 2026 at 6:51 PM
PXD072235 🚨

Epitranscriptomic editing screening identifies functional m6A sites in prostate cancer cells.

🚨 New dataset alert! 🚨
October 11, 2026 at 11:00 AM
One RNA-modifying enzyme can influence #cancer across multiple tumors.
This review explores FTO’s context-dependent roles in cancer through #m6A demethylation, highlighting FTO as a promising therapeutic target. #Epitranscriptomic
#GenesAndDiseases: doi.org/10.1016/j.ge...
October 11, 2026 at 3:06 PM